These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 19913921)

  • 1. The HIV-1 transgenic rat as a model for HIV-1 infected individuals on HAART.
    Peng J; Vigorito M; Liu X; Zhou D; Wu X; Chang SL
    J Neuroimmunol; 2010 Jan; 218(1-2):94-101. PubMed ID: 19913921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular biological assessment methods and understanding the course of the HIV infection.
    Katzenstein TL
    APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
    Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation Effect of HIV-1 Viral Proteins and Nicotine on Expression of the Immune-Related Genes in Brain of the HIV-1 Transgenic Rats.
    Yang Z; Nesil T; Connaghan KP; Li MD; Chang SL
    J Neuroimmune Pharmacol; 2016 Sep; 11(3):562-71. PubMed ID: 27147085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of GBV-C infection in HIV-1 infected patients.
    Canducci F; Uberti Foppa C; Boeri E; Racca S; Gallotta G; Grasso MA; Calori G; Lazzarin A; Clementi M
    J Biol Regul Homeost Agents; 2003; 17(2):191-4. PubMed ID: 14518722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Delta32 deletion.
    Laurichesse JJ; Persoz A; Theodorou I; Rouzioux C; Delfraissy JF; Meyer L
    HIV Med; 2007 May; 8(4):213-9. PubMed ID: 17461848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Older age and plasma viral load in HIV-1 infection.
    Goodkin K; Shapshak P; Asthana D; Zheng W; Concha M; Wilkie FL; Molina R; Lee D; Suarez P; Symes S; Khamis I
    AIDS; 2004 Jan; 18 Suppl 1():S87-98. PubMed ID: 15075503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human immunodeficiency virus type 1 RNA in peripheral blood mononuclear cells of patients receiving prolonged highly active antiretroviral therapy.
    Zhang J; Crumpacker CS
    J Infect Dis; 2001 Nov; 184(10):1341-4. PubMed ID: 11679927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
    Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
    HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of viral replication with highly active antiretroviral therapy has no impact on the functional profile of HIV-specific CD8(+) T cells.
    López M; Soriano V; Rallón N; Cascajero A; González-Lahoz J; Benito JM
    Eur J Immunol; 2008 Jun; 38(6):1548-58. PubMed ID: 18421792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Virological characterization of patients treated early is able to control HIV-1 replication after multiple cycles of structured therapy interruption.
    Rozera G; Abbate I; D'Offizi G; Corpolongo A; Narciso P; Vlassi C; Martini F; Calcaterra S; Capobianchi MR
    J Med Virol; 2007 Aug; 79(8):1047-54. PubMed ID: 17597482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Highly active antiretroviral therapy started during pregnancy or postpartum suppresses HIV-1 RNA, but not DNA, in breast milk.
    Shapiro RL; Ndung'u T; Lockman S; Smeaton LM; Thior I; Wester C; Stevens L; Sebetso G; Gaseitsiwe S; Peter T; Essex M
    J Infect Dis; 2005 Sep; 192(5):713-9. PubMed ID: 16088820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
    Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
    Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increase of HIV-1 pro-viral DNA per million peripheral blood mononuclear cells in patients with advanced HIV disease (CD4<200 cells/mm3) receiving interleukin 2 combined with HAART versus HAART alone (ANRS-082 trial).
    Delaugerre C; Gourlain K; Tubiana R; Carcelain G; Marcelin AG; Chouquet C; Mouroux M; Duvivier C; Autran B; Costagliola D; Katlama C; Calvez V
    Antivir Ther; 2003 Jun; 8(3):233-7. PubMed ID: 12924540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal fluid viral loads reach less than 2 copies/ml in HIV-1-infected patients with effective antiretroviral therapy.
    Yilmaz A; Svennerholm B; Hagberg L; Gisslén M
    Antivir Ther; 2006; 11(7):833-7. PubMed ID: 17302245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of evidence for protease evolution in HIV-1-infected patients after 2 years of successful highly active antiretroviral therapy.
    Parera M; Ibañez A; Clotet B; Martinez MA
    J Infect Dis; 2004 Apr; 189(8):1444-51. PubMed ID: 15073682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene expression and viral prodution in latently infected, resting CD4+ T cells in viremic versus aviremic HIV-infected individuals.
    Chun TW; Justement JS; Lempicki RA; Yang J; Dennis G; Hallahan CW; Sanford C; Pandya P; Liu S; McLaughlin M; Ehler LA; Moir S; Fauci AS
    Proc Natl Acad Sci U S A; 2003 Feb; 100(4):1908-13. PubMed ID: 12552096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study.
    Kaufmann GR; Perrin L; Pantaleo G; Opravil M; Furrer H; Telenti A; Hirschel B; Ledergerber B; Vernazza P; Bernasconi E; Rickenbach M; Egger M; Battegay M;
    Arch Intern Med; 2003 Oct; 163(18):2187-95. PubMed ID: 14557216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption.
    Harrer E; Bäuerle M; Ferstl B; Chaplin P; Petzold B; Mateo L; Handley A; Tzatzaris M; Vollmar J; Bergmann S; Rittmaier M; Eismann K; Müller S; Kalden JR; Spriewald B; Willbold D; Harrer T
    Antivir Ther; 2005; 10(2):285-300. PubMed ID: 15865223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.